Icro Meattini, MD, University of Florence, Florence, Italy, shares the results of the Phase III SAFE (NCT02236806) trial investigating beta blockers and/or ACE inhibitors as cardioprotective strategy for patients affected by nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy. The primary end point was defined as detection of any subclinical impairment (worsening 10%) in myocardial function and deformation measured at 24 months using 3-dimensional (3D) echocardiography, left ventricular ejection fraction (LVEF), and global longitudinal strain (GLS). The trial demonstrated the administration of beta blockers and/or ACE inhibitors as a cardioprotective strategy is well tolerated and protect against cancer therapy–related LVEF decline and heart remodeling. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.